Minocycline and psychoneuroimmunology in schizophrenia
Cristiano Chaves(Queen's University), Jaime E. C. Hallak(Conselho Nacional de Desenvolvimento Científico e Tecnológico), José Alexandre S. Crippa(Universidade de São Paulo), Lauro Wichert‐Ana(Center for Translational Molecular Medicine), Kathryn G. Todd(University of Alberta), Emerson Nobuyuki Itikawa(Universidade de São Paulo), Glen B. Baker(University of Alberta), João Paulo Maia‐de‐Oliveira(Universidade Federal do Rio Grande do Norte), Serdar Dursun(Centre for Addiction and Mental Health), Antônio Waldo Zuardi(Universidade de São Paulo), Cristiane Reberte de Marque(Universidade de Ribeirão Preto)
Progress in Neuro-Psychopharmacology and Biological Psychiatry
May 6, 2010
Cited by 1
Related Papers
Treatment-Resistant Schizophrenia: Treatment Response and Resistance in Psychosis (TRRIP) Working Group Consensus Guidelines on Diagnosis and Terminology
|American Journal of Psychiatry|2016|1.1k
Rapid antidepressant effects of the psychedelic ayahuasca in treatment-resistant depression: a randomized placebo-controlled trial
|Psychological Medicine|2018|819
Cannabidiol Reduces the Anxiety Induced by Simulated Public Speaking in Treatment-Naïve Social Phobia Patients
|Neuropsychopharmacology|2011|763
Neural basis of anxiolytic effects of cannabidiol (CBD) in generalized social anxiety disorder: a preliminary report
|Journal of Psychopharmacology|2010|530
Antidepressant effects of a single dose of ayahuasca in patients with recurrent depression: a preliminary report
|Brazilian Journal of Psychiatry|2015|484